Adaptimmune Therapeutics, an onco-immunology company developing treatments to boost the ability of a person’s own immune system to recognize and destroy cancer cells, said Friday it has adopted the name “SPEAR T-Cells” to describe its priority technology.
SPEAR is an acronym for specific peptide enhanced affinity receptor T-cells. T-cells, also known as T-lymphocytes, are subtypes of white blood cells that develop in the thymus gland and are responsible for a variety of immune system responses.
To read the full article, click here.
Local
Breaking news and the stories that matter to your neighborhood.
For more business news, visit Philadelphia Business Journal.
Copyright bizjournal
